D-dimer a predictive test for thrombosis risk in Chronic Myeloid Leukemia patients

Abstract

Background; A systemic activation of blood coagulation and pro-coagulant change in the hemostatic system has frequently been observed in cancer patients, even in the absence of venous thromboembolism. Chronic myeloid leukemia (CML), also known as “chronic myelogenous leukemia,” is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. D-dimer is a biomarker that globally indicates the activation of homeostasis and fibrinolysis. Studies conducted that patients of myeloid leukemia, some were during treatment, there was an increase of fibrinolysis activity as a significant increase of D-dimer was observed after 24h of treatment, suggested the influence of the cure on coagulation and fibrinolysis systems. Materials and Methods; The study recruited 42 patients diagnosed by Chronic Myeloid Leukemia. Venous blood was collected for estimation of total white blood cells count, blast count and D-dimer assay. Results and Conclusions; CML patients were at risk for thrombosis. Positivity of D-dimer was not related to leukocytosis nor treatment. Elevation of the D-dimer was associated with the blast count.